| Literature DB >> 34728689 |
Ha Min Sung1, Seung-Hwa Lee2,3, Ah Ran Oh4,5, Sojin Kim4, Jeayoun Kim4, Joonhee Gook4, Jae Ni Jang4, Jungchan Park6,7.
Abstract
Predictive factors associated with postoperative mortality have not been extensively studied in plastic and reconstructive surgery. Neutrophil-lymphocyte ratio (NLR), a systemic inflammation index, has been shown to have a predictive value in surgery. We aimed to evaluate association between preoperative NLR and postoperative outcomes in patients undergoing plastic and reconstructive surgery. From January 2011 to July 2019, we identified 7089 consecutive adult patients undergoing plastic and reconstructive surgery. The patients were divided according to median value of preoperative NLR of 1.84. The low NLR group was composed of 3535 patients (49.9%), and 3554 patients (50.1%) were in the high NLR group. The primary outcome was mortality during the first year, and overall mortality and acute kidney injury were also compared. In further analysis, outcomes were compared according to quartile of NLR, and a receiver operating characteristic curve was constructed to estimate the threshold associated with 1-year mortality. This observational study showed that mortality during the first year after plastic and reconstructive surgery was significantly increased in the high NLR group (0.7% vs. 3.5%; hazard ratio, 4.23; 95% confidence interval, 2.69-6.63; p < 0.001), and a graded association was observed between preoperative NLR and 1-year mortality. The estimated threshold of preoperative NLR was 2.5, with an area under curve of 0.788. Preoperative NLR may be associated with 1-year mortality after plastic and reconstructive surgery. Further studies are needed to confirm our findings.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34728689 PMCID: PMC8564523 DOI: 10.1038/s41598-021-00901-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics according to the median value of preoperative NLR.
| Entire population | Propensity score matched population | |||||||
|---|---|---|---|---|---|---|---|---|
| Low NLR (N = 3535) | High NLR (N = 3554) | ASD | Low NLR (N = 3305) | High NLR (N = 3305) | ASD | |||
| Preoperative NLR | 1.33 (± 0.49) | 3.49 (± 3.72) | 1.32 (± 0.32) | 3.37 (± 2.99) | ||||
| Age (years)a | 46 (37–55) | 45 (36–55) | 0.8 | 0.6 | 46 (36–54) | 44 (35–54) | 0.01 | 2.3 |
| Malea | 1002 (28.3) | 1164 (32.8) | < 0.001 | 9.6 | 959 (29.0) | 1019 (30.8) | 0.11 | 4 |
| Smokinga | 352 (10.0) | 386 (10.9) | 0.21 | 3 | 337 (10.2) | 343 (10.4) | 0.84 | 0.6 |
| Alcohola | 925 (26.2) | 849 (23.9) | 0.03 | 5.3 | 812 (24.6) | 790 (23.9) | 0.55 | 1.6 |
| Hypertensiona | 165 (4.7) | 246 (6.9) | < 0.001 | 9.7 | 160 (4.8) | 173 (5.2) | 0.5 | 1.8 |
| 0.31 (± 0.96) | 0.42 (± 1.16) | < 0.001 | 9.7 | 0.32 (± 0.96) | 0.34 (± 1.02) | 0.42 | 2 | |
| Myocardial infarction | 6 (0.2) | 6 (0.2) | 5 (0.2) | 3 (0.1) | ||||
| Heart failure | 8 (0.2) | 17 (0.5) | 7 (0.2) | 9 (0.3) | ||||
| Peripheral vascular disease | 9 (0.3) | 10 (0.3) | 9 (0.3) | 6 (0.2) | ||||
| Cerebrovascular disease | 49 (1.4) | 61 (1.7) | 48 (1.5) | 50 (1.5) | ||||
| Dementia | 0 | 1 (0.0) | 1 (0.0) | 1 (0.0) | ||||
| Chronic pulmonary disease | 1 (0.0) | 3 (0.1) | 1 (0.0) | 1 (0.0) | ||||
| Rheumatic disease | 13 (0.4) | 50 (1.4) | 13 (0.4) | 37 (1.1) | ||||
| Peptic ulcer disease | 0 | 0 | 0 | 0 | ||||
| Mild liver disease | 117 (3.3) | 127 (3.6) | 107 (3.2) | 100 (3.0) | ||||
| Diabetes without complication | 94 (2.7) | 174 (4.9) | 89 (2.7) | 122 (3.7) | ||||
| Diabetes with complication | 36 (1.0) | 70 (2.0) | 33 (1.0) | 42 (1.3) | ||||
| Hemiplegia | 8 (0.2) | 13 (0.4) | 8 (0.2) | 7 (0.2) | ||||
| Renal disease | 28 (0.8) | 86 (2.4) | 25 (0.8) | 55 (1.7) | ||||
| Any malignancy | 192 (5.4) | 162 (4.6) | 185 (5.6) | 152 (4.6) | ||||
| Moderate to severe liver disease | 0 | 5 (0.1) | 0 | 1 (0.0) | ||||
| Metastatic solid tumor | 0 | 0 | 0 | 0 | ||||
| Human immunodeficiency virus | 0 | 1 (0.0) | 0 | 0 | ||||
| Hemoglobin (g/dL)a | 13.11 (± 1.84) | 13.14 (± 1.81) | 0.5 | 1.3 | 13.14 (± 1.80) | 13.14 (± 1.78) | 0.92 | 0.2 |
| Creatinine (mg/dL)a | 0.78 (± 0.42) | 0.83 (± 0.68) | < 0.001 | 9.1 | 0.78 (± 0.39) | 0.79 (± 0.46) | 0.44 | 1.9 |
| Duratrion (h)a | 3.33 (1.58–4.85) | 3.18 (1.33–4.66) | < 0.001 | 8.8 | 3.28 (1.55–4.78) | 3.37 (1.62–4.78) | 0.63 | 2.1 |
| General anesthesiaa | 3385 (95.8) | 3212 (90.4) | < 0.001 | 21.3 | 3158 (95.6) | 3157 (95.5) | > 0.99 | 0.1 |
| Head and neck | 514 (14.5) | 512 (14.4) | 476 (14.4) | 471 (14.3) | ||||
| Trunk and extremities | 649 (18.4) | 693 (19.3) | 600 (18.2) | 641 (19.4) | ||||
| Breast | 1607 (45.5) | 1610 (45.3) | 1510 (45.7) | 1507 (45.6) | ||||
| Aesthetic surgery | 97 (2.7) | 73 (2.1) | 88 (2.7) | 67 (2.0) | ||||
| Mass excision | 668 (18.9) | 666 (18.7) | 631 (19.1) | 619 (18.7) | ||||
Values are n (%), mean (± standardized difference), or median (interquartile range).
ASD absolute standardized mean difference, NLR neutrophil-to-lymphocyte ratio.
aFollowing variables were retained for propensity score matching.
Clinical outcomes according to the median value of preoperative NLR.
| Low | High | Unadjusted HR/OR (95% CI) | Adjusted HR/OR (95% CI) | |||
|---|---|---|---|---|---|---|
| N = 3535 | N = 3554 | |||||
| One-year mortality | 23 (0.7) | 126 (3.5) | 5.59 (3.59–8.71) | < 0.001 | 4.23 (2.69–6.63) | < 0.001 |
| Overall mortality | 106 (3.0) | 242 (6.8) | 2.39 (1.90–3.00) | < 0.001 | 2.06 (1.64–2.60) | < 0.001 |
| Acute kidney injury | ||||||
| Any | 12 (0.3) | 55 (1.5) | 4.62 (2.47–8.63) | < 0.001 | 3.38 (1.74–6.59) | < 0.001 |
| Stage 1 | 11 (0.3) | 48 (1.4) | 4.39 (2.27–8.46) | < 0.001 | 3.05 (1.51–6.17) | 0.002 |
| Stage 2 | 1 (0.0) | 7 (0.2) | 6.97 (0.86–56.72) | 0.07 | 6.87 (0.83–56.90) | 0.07 |
| N = 3305 | N = 3305 | |||||
| One-year mortality | 21 (0.6) | 96 (2.9) | 13.17 (6.98–24.82) | < 0.001 | ||
| Overall mortality | 96 (2.9) | 193 (5.8) | 10.82 (6.38–18.35) | < 0.001 | ||
| Acute kidney injury | ||||||
| Any | 10 (0.3) | 35 (1.1) | 3.21 (1.68–6.63) | < 0.001 | ||
| Stage 1 | 9 (0.3) | 30 (0.9) | 3.02 (1.53–6.51) | 0.003 | ||
| Stage 2 | 1 (0.0) | 5 (0.2 | 5.01 (0.81–95.9) | 0.14 | ||
Mortalities were reported with HR, and acute kidney injury was reported with OR.
Multivariable analysis retained age, male, alcohol, preoperative creatinine level, Charlson comorbidity index, operative duration, and general anesthesia.
Propensity score matching analysis retained age, male, smoking, alcohol, preoperative creatinine/hemoglobin levels, hypertension, Charlson comorbidity index, operative duration, and general anesthesia.
NLR neutrophil-to-lymphocyte ratio, HR hazard ratio, OR odds ratio.
Clinical outcomes according to quartile value of preoperative NLR.
| 1st quartile (N = 1787) | 2nd quartile (N = 1737) | 3rd quartile (N = 1769) | 4th quartile (N = 1737) | |
|---|---|---|---|---|
| NLR range | < 1.35 | < 1.84 | < 2.61 | |
| One-year mortality, number (%) | 9 (0.5) | 14 (0.8) | 20 (1.1) | 106 (6.0) |
| Unadjusted HR (95% CI) | Ref | 1.59 (0.69–3.66) | 1.51 (0.02–2.23) | 2.30 (1.84–2.89) |
| 0.28 | 0.04 | < 0.001 | ||
| Overall mortality, number (%) | 51 (2.9) | 55 (3.2) | 67 (3.8) | 175 (9.8) |
| Unadjusted HR (95% CI) | Ref | 1.12 (0.76–1.64) | 1.16 (0.96–1.39) | 1.56 (1.40–1.73) |
| 0.56 | 0.12 | < 0.001 | ||
| Any, number (%) | 3 (0.2) | 9 (0.5) | 10 (0.6) | 45 (2.5) |
| Unadjusted OR (95% CI) | Ref | 3.09 (0.83–11.41) | 1.84 (0.96–3.50) | 2.49 (1.69–3.68) |
| 0.09 | 0.07 | < 0.001 | ||
| Stage 1, number (%) | 2 (0.1) | 9 (0.5) | 8 (0.5) | 40 (2.3) |
| Unadjusted OR (95% CI) | Ref | 4.63 (1.00–21.46) | 2.01 (0.93–4.37) | 2.74 (1.71–4.40) |
| 0.05 | 0.08 | < 0.001 | ||
| Stage 2, number (%) | 1 (0.1) | 0 | 2 (0.1) | 5 (0.3) |
| Unadjusted OR (95% CI) | Ref | 1.42 (0.43–4.72) | 1.72 (0.84–3.51) | |
| 0.57 | 0.14 | |||
NLR neutrophil-to-lymphocyte ratio, HR hazard ratio, OR odds ratio.
Figure 1Kaplan Meier curves of the groups divided by median value for mortality in the entire population during (A) 1-year and (B) overall follow-up periods, and propensity matched population during (C) 1-year and (D) overall follow-up periods.
Figure 2Kaplan Meier curves of the groups divided by quartile for mortality during 1-year.
Figure 3Subgroup analysis according to types of plastic and reconstructive surgery.
Figure 4Subgroup analysis according to general anesthesia.
Figure 5Receiver-operating characteristic plots of neutrophil–lymphocyte ratio associated with 1-year mortality for plastic and reconstructive surgery.